Segmentation by type isolates four distinct organocatalyst families, each adding unique value to the market landscape. Small‑molecule organocatalysts remain the largest category, offering versatile, low‑cost platforms for asymmetric synthesis and accounting for the bulk of sales due to their broad applicability. Peptide‑based organocatalysts capture a growing niche, especially in biocatalysis, where their inherent chirality and biodegradability command higher margins. Polymer‑supported organocatalysts contribute a modest yet expanding share, as they enable catalyst recovery and reuse, aligning with circular economy objectives. Bifunctional/chiral organocatalysts—including thioureas, imidazolidinones, and N‑heterocyclic carbenes—drive premium pricing through superior enantioselectivity and reaction scope, appealing to high‑value pharmaceutical and fine‑chemical producers. The relative market weight of each type reflects a balance between cost considerations, performance requirements, and regulatory pressures, collectively underpinning the overall Organocatalyst market growth.